Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G9-G12. Epub 2007 Nov 1.

Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.

Author information

1
INSERM, U 841, Institut Mondor de recherche Biomédicale Hôpital Henri Mondor 94010 Créteil, France.

Abstract

Cannabinoid receptors (CB1 and CB2) and their endogenous ligands (endocannabinoids) have recently emerged as novel mediators of liver diseases. Endogenous activation of CB1 receptors promotes nonalcoholic fatty liver disease (NAFLD) and progression of liver fibrosis associated with chronic liver injury; in addition, CB1 receptors contribute to the pathogenesis of portal hypertension and cirrhotic cardiomyopathy. CB2 receptor-dependent effects are also increasingly characterized, including antifibrogenic effects and regulation of liver inflammation during ischemia-reperfusion and NAFLD. It is likely that the next few years will allow us to delineate whether molecules targeting CB1 and CB2 receptors are useful therapeutic agents for the treatment of chronic liver diseases.

PMID:
17975129
DOI:
10.1152/ajpgi.00467.2007
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center